Tioga Drug Gets Fast Track Status

6/6/11Follow @bvbigelow

San Diego’s Tioga Pharmaceuticals, a virtual biotech with the equivalent of three full-time employees, said the FDA has granted “fast track” designation to asimadoline, a compound Tioga is investigating for treating patients with diarrhea-predominant irritable bowel syndrome. Tioga is in a late-stage clinical trial of the drug, which is being conducted under a special protocol assessment agreement with the FDA.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

By posting a comment, you agree to our terms and conditions.